Entrectinib: Known uses and market status in Canada
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Entrectinib, so there is currently no new predicted indication. The drug’s recorded uses are listed below. These are the drug’s own recorded uses, not model candidates.
Quick overview
Item
Content
New predicted indications
None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug
1
Evidence level
Not applicable
Canada Market Status
Marketed (marketed DINs: 2 of 2)
Number of DINs
2 (marketed: 2)
Known uses recorded for this drug
Approved (supported by a licence or label)
Indication
Source
non-small-cell lung carcinoma
licence in another country
Related to an approved indication (same disease category)
Indication
Approved category
none
none
Relations recorded in the knowledge graph (no approval found)
Indication
none
Canada Market Information
Licence
Product
Dosage form
Status
02495015
ROZLYTREK
Valid
02495007
ROZLYTREK
Valid
Cytotoxicity
Item
Content
Cytotoxicity Classification
Targeted therapy (kinase inhibitor)
Myelosuppression Risk
Please refer to the package insert warnings and precautions
Emetogenicity Classification
Please refer to the package insert warnings and precautions
Monitoring Items
Please refer to the package insert warnings and precautions
Handling Protection
Please refer to the package insert warnings and precautions
Safety Considerations
Drug interactions: The interaction screening returned 100 interacting drugs, 20 of which were included in the data compiled for this report. The main Major interactions are:
Aprepitant
Dexamethasone
Clarithromycin
Dolasetron
Examples of Moderate interactions include famotidine, loperamide, cimetidine, budesonide, levofloxacin, naltrexone, saxagliptin, empagliflozin and several bowel-preparation agents (bisacodyl, picosulfuric acid, polyethylene glycol, sodium sulfate). Minor interactions include naloxegol and metronidazole.
Possible safety signals from the literature: A 2025 case report describes pulmonary tumor thrombotic microangiopathy (PTTM) progressing during entrectinib therapy in a patient with NTRK fusion-positive colon cancer, despite a marked tumour response. This is a single case report and should be monitored, not over-interpreted.
Please refer to the package insert for warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.